Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc., a Delaware corporation and emerging growth company, on November 18, 2025. The report discloses a material event under Item 8.01 (Other Events) regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the passing of Andrew H. Woo, M.D., Ph.D., a director of the Company, on November 14, 2025. Dr. Woo had served on the Board of Directors since the Company's initial public offering in June 2021.
Management Commentary and Risks
William B. Horne, Chairman of the Board, issued a statement expressing great sadness over Dr. Woo's passing. He described Dr. Woo as an outstanding director who provided exceptional inspiration and will be deeply missed as both a respected colleague and a friend. The Company extended its deepest condolences to his family and friends. No specific financial risks, contingencies, or unusual items were detailed in this filing.
Key Facts for Investor Verification
- Dr. Andrew H. Woo, M.D., Ph.D., passed away on November 14, 2025.
- Dr. Woo was a long-serving director since the June 2021 IPO.
- The Company has not yet announced a replacement for the Board vacancy in this filing.
- No financial data or operational updates were included in this specific report.